Figure 1. Warangalone decreases the viability of breast cancer cells. (A) MDA-MB-231, MCF7, SKBR3, ZR75-1 and MCF-10A cells were treated with warangalone of different concentrations for 12, 24, and 48 h. Cell viability was detected by MTT assay. One-way ANOVA was used to compare between the control and warangalone treatment groups (n ≥ 3). *P < 0.05, **P < 0.01, ***P < 0.001 compared to the respective control group. (B) MDA-MB-231/MCF7 cells were treated with 0, 10, 20 and 30 μM warangalone for 24 h. Cell morphology was observed by microscopy.